Premium
Expression of interleukin 15 (IL‐15) in human rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma
Author(s) -
Lollini PierLuigi,
Palmieri Gabriella,
De Giovanni Carla,
Landuzzi Lorena,
Nicoletti Giordano,
Rossi Ilaria,
Griffoni Cristiana,
Frabetti Flavia,
Scotlandi Katia,
Benini Stefania,
Baldini Nicola,
Santoni Angela,
Nanni Patrizia
Publication year - 1997
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19970529)71:5<732::aid-ijc7>3.0.co;2-s
Subject(s) - rhabdomyosarcoma , osteosarcoma , sarcoma , ewing's sarcoma , embryonal rhabdomyosarcoma , cancer research , cytokine , cell culture , alveolar rhabdomyosarcoma , pathology , medicine , biology , immunology , genetics
Interleukin 15 (IL‐15) is a recently discovered cytokine that stimulates lymphocyte proliferation and migration via a trimeric receptor sharing the β and γ signal transducing chains with the IL‐2 receptor. IL‐15 is typically produced by normal cells that do not release IL‐2, but little information is currently available on human tumors. To assess whether human musculo‐skeletal sarcomas produce IL‐15, we analyzed surgical specimens and cell lines obtained from rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma. IL‐15 mRNA was present in 9/9 surgical specimens (3 Ewing's sarcomas, 5 osteosarcomas and 1 rhabdomyosarcoma). The analysis of a panel of cell lines (7 derived from Ewing's sarcoma, 12 from osteosarcoma and 5 from rhabdomyosarcoma) showed that all rhabdomyosarcoma and osteosarcoma cell lines expressed IL‐15 mRNA at levels ranging from low to high, while Ewing's sarcoma cells contained little or no IL‐15 message. ELISA assays showed IL‐15 release in a subset of rhabdomyosarcomas and osteosarcomas, but not in Ewing's sarcoma. The highest production of IL‐15, in the picogram/ml range, was found in rhabdomyosarcoma cell lines RH30 and RD. Int. J.Cancer 71:732‐736, 1997. © 1997 Wiley‐Liss Inc.